Key result
Folic acid significantly reversed celecoxib-induced cardiotoxicity, which manifested as increases in LDH, Tn-T, TNF-α, CK-MB, SBP, and HR (p < 0.001), in a doxorubicin heart failure rat model.
Why the study?
Does folic acid reduce celecoxib-induced cardiotoxicity in a doxorubicin heart failure rat model?
Does folic acid reduce celecoxib-induced cardiotoxicity in a doxorubicin heart failure rat model?
Folic acid protects against celecoxib-induced cardiotoxicity in a rat model of doxorubicin-induced cardiomyopathy.
Folic acid may attenuate celecoxib cardiotoxicity in doxorubicin rat models; hypothesis-generating and should not change practice.
CONTEXT: The cardiotoxic effect of selective cyclo-oxygenase-2 inhibitors is well known. While rofecoxib and valdecoxib have been withdrawn, celecoxib remains on the market. Folic acid, a naturally occurring vitamin, has been shown to reduce myocardial ischemia and post-reperfusion injury in rats. OBJECTIVE: This study examined the cardiac effects of celecoxib and folic acid on doxorubicin-induced cardiomyopathy in rats. MATERIALS AND METHODS: Cardiomyopathy was induced in male Wistar rats with six intraperitoneal injections of 2.5 mg/kg doxorubicin over a period of two weeks. The effect of 28 days of celecoxib (100 mg/kg/day) and its combination with folic acid (10 mg/kg/day) was studied on doxorubicin-induced cardiomyopathy according to serum lactate dehydrogenase (LDH), creatine kinase (CK-MB), troponin-T (Tn-T), tumor necrosis factor alpha (TNF-α), cardiac thiobarbituric acid reactive substance (TBARS), and glutathione (GSH) levels as well as systolic blood pressure (SBP), heart rate (HR) and ultrastructural studies. RESULTS: Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0.001) and TBARS (p < 0.01) levels and a significant decrease in the GSH (p < 0.05) level when used alone or administered with doxorubicin. However, the combination of folic acid with celecoxib caused a significant reversal of these parameters and reduced the cardiotoxicity of celecoxib that was aggravated by doxorubicin. The ultrastructural study also revealed myocardial protection with this combination. DISCUSSION AND CONCLUSION: Folic acid protects against the cardiotoxic effects of celecoxib, which are aggravated in the presence of doxorubicin. Folic acid may act as a useful adjunct in patients who are taking celecoxib.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2017) studied doxorubicin-induced cardiomyopathy. Folic acid vs. Celecoxib alone or with doxorubicin was evaluated on serum LDH, CK-MB, Tn-T, TNF-α, TBARS, GSH levels, SBP, HR, and ultrastructural changes. Folic acid significantly reversed celecoxib-induced cardiotoxicity, which manifested as increases in LDH, Tn-T, TNF-α, CK-MB, SBP, and HR (p < 0.001), in a doxorubicin heart failure rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: